Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for T2DM management, have emerged as promising candidates for MASLD treatment due to their metabolic and weight-reducing effects [14]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.